B.Riley FBR analyst Bryan Maher reiterated a Buy rating on Global Medical REIT (NYSE: GMRE) today and set a price target of $11. The company’s shares closed yesterday at $8.96.
According to TipRanks.com, Maher is a 3-star analyst with an average return of 3.3% and a 60.3% success rate. Maher covers the Financial sector, focusing on stocks such as Industrial Logistics Properties Trust, Government Properties Income Trust, and Senior Housing Properties Trust.
Global Medical REIT has an analyst consensus of Moderate Buy, with a price target consensus of $10.50, representing a 17.2% upside. In a report issued on August 8, Cantor Fitzgerald also reiterated a Buy rating on the stock with a $10 price target.
.
See today’s analyst top recommended stocks >>
The company has a one-year high of $9.83 and a one-year low of $6.34. Currently, Global Medical REIT has an average volume of 115.5K.
Based on the recent corporate insider activity of 6 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of GMRE in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Global Medical REIT, Inc. operates as a development stage company that intends to develop and manage a portfolio of healthcare real estate assets and properties. The company was founded on March 18, 2011 and is headquartered in Bethesda, MD.
